March 23, 2018 / 12:18 PM / a month ago

BRIEF-Pfizer's Quit-Smoking Chantix Fails In A Study In Adolescent Smokers

March 23 (Reuters) - Pfizer Inc:

* PFIZER REPORTS TOP-LINE RESULTS FROM A STUDY OF CHANTIX®/CHAMPIX® (VARENICLINE) IN ADOLESCENT SMOKERS

* PFIZER INC - STUDY DID NOT MEET ITS PRIMARY ENDPOINT

* PFIZER INC - ADVERSE EVENT PROFILE OF CHANTIX/CHAMPIX OBSERVED IN STUDY OF ADOLESCENT SMOKERS WAS SIMILAR TO THAT SEEN IN STUDIES OF ADULTS

* PFIZER - IN TRIAL, MOST COMMON ADVERSE EVENTS THAT OCCURRED IN AT LEAST 5 PERCENT OF PATIENTS WERE NAUSEA, HEADACHE, VOMITING, OTHERS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below